Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Description

This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in \[18F\]F AraG PET signal before and after CkIT therapy, and to correlate this change in \[18F\]F AraG PET signal with a radiographic response.

Conditions

Non Small Cell Lung Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in \[18F\]F AraG PET signal before and after CkIT therapy, and to correlate this change in \[18F\]F AraG PET signal with a radiographic response.

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Condition
Non Small Cell Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Palo Alto

Palo Alto Veterans Institute of Research, Palo Alto, California, United States, 94304

Sacramento

Sutter Cancer Center, Sacramento, California, United States, 95816

Stony Brook

Stony Brook University, Stony Brook, New York, United States, 11794

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients with a histologically confirmed NSCLC and planned to undergo immunotherapy as monotherapy or as combination therapy with concurrent as treatment for advanced/metastatic disease.
  • 2. RECIST measurable disease.
  • 3. ECOG performance status of 0, 1 or 2.
  • 4. Life expectancy \>/= 6 months at enrollment.
  • 1. Serious comorbidities that in the opinion of the investigator/sponsor could compromise protocol objectives.
  • 2. Pregnant women or nursing mothers.
  • 3. Patients with severe claustrophobia.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

CellSight Technologies, Inc.,

Deepak Behera, MD, PRINCIPAL_INVESTIGATOR, CellSight Technologies, Inc.

Study Record Dates

2024-10-15